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Simple Summary: Mitochondria are the core energy-generating units found within a cell. In addition,
mitochondria harbor molecular factors that are essential, upon their release from these organelles,
for triggering cell suicide program or apoptosis. Recent research has pointed to the critical role that
the mitochondrial shape, which is dynamically flexible rather than rigid, plays in regulating both,
bioenergetics metabolism and programmed cell death. Given that activating apoptosis specifically in
tumor cells can be an advantage for eradicating cancer by chemotherapy, we address the simple idea
of whether pharmacological stimulation of mitochondrial dynamics can benefit cancer patients with
solid tumors. We propose a model, in which mitochondrial fragmented phenotype and mitochondrial
reactive oxygen species (ROS) production are interconnected within a self-propagating cycle that
relies for its function on nuclear stress signaling pathways. We conclude that manipulation of
mitochondrial dynamics may be at the heart of chemotherapeutic approaches targeting cancers with
elevated oxidative stress.
Abstract: Cancer is one of the world’s deadliest afflictions. Despite recent advances in diagnostic
and surgical technologies, as well as improved treatments of some individual tumor types, there is
currently no universal cure to prevent or impede the uncontrolled proliferation of malignant cells.
Targeting tumors by inducing apoptosis is one of the pillars of cancer treatment. Changes in mito-
chondrial morphology precede intrinsic apoptosis, but mitochondrial dynamics has only recently
been recognized as a viable pharmacological target. In many cancers, oncogenic transformation is
accompanied by accumulation of elevated cellular levels of ROS leading to redox imbalance. Hence,
a common chemotherapeutic strategy against such tumor types involves deploying pro-oxidant
agents to increase ROS levels above an apoptotic death-inducing threshold. The aim of this chapter
is to investigate the benefit of stimulating mitochondrial fission-dependent production of ROS for
enhanced killing of solid tumors. The main question to be addressed is whether a sudden and
abrupt change in mitochondrial shape toward the fragmented phenotype can be pharmacologically
harnessed to trigger a burst of mitochondrial ROS sufficient to initiate apoptosis specifically in cancer
cells but not in non-transformed healthy tissues.
Keywords: mitochondria; reactive oxygen species; cancer; chemotherapy; oxidative stress; stress
signaling; mitochondrial dynamics; mitophagy; apoptosis; cyclin C
1. Introduction
During oxidative metabolism, incomplete reduction of oxygen leads to the formation
of highly active compounds known as reactive oxygen species (ROS) [1]. ROS at physiolog-
ical levels serve as intra- and extracellular signaling molecules but prolonged or excessive
production of ROS can lead to the damage of proteins, DNA, lipids, or other cellular
components [2]. Depending on its severity and nature, oxidative stress can activate pro-
survival pathways such as mitophagy or triggering of regulated cell death (RCD) responses
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such as intrinsic apoptosis [3]. One of the common features of stress-induced mitophagy
and apoptosis is increased fragmentation of the mitochondrial network. The ability of
mitochondria to sense and dynamically respond to oxidative changes suggests the presence
of redox-sensing signaling pathways that stimulate the mitochondrial fission machinery [4].
In addition, the critical decision whether to repair oxidative damage and survive, or un-
dergo RCD, depends also on the detoxification and scavenging capacity of antioxidant
mechanisms controlling cellular redox homeostasis [5,6]. Given that evasion of apoptosis
is one of the hallmarks of cancer progression, it is of paramount importance to grasp a
detailed molecular understanding of how mitochondrial dynamics and redox homeostasis
modulate the cell’s decision to survive or undergo cell death [7]. On one hand, cancer cells
produce excessive amounts of ROS as a byproduct of their reprogrammed metabolism to
sustain increased metabolic needs for tumor growth [8]. On the other hand, elevated oxida-
tive status may represent an Achilles’ heel for some cancer types as it may be more feasible
to target these tumors with pro-oxidant chemotherapy [9]. The following sections review
the basic concepts of mitochondrial dynamics, mitochondrial quality control pathways,
redox biology, and mitochondrial-dependent apoptosis in the context of carcinogenesis.
2. Stress-Induced Signaling Directs Cell Fate Decisions
2.1. Mitochondria Are Highly Dynamic Organelles
Mitochondria form a highly flexible and interconnected network, in which individual
units undergo frequent events of fission and fusion (Video S1) [10]. Enzymes responsible
for mediating the highly conserved process of mitochondrial dynamics involve large fis-
sion and fusion guanosine 5′-triphosphatases (GTPases) such as dynamin-related protein 1
(Drp1) or dynamin 2 (Dnm2) and mitofusins Mfn1 or Mfn2, respectively [11]. In addition,
inner mitochondrial membrane (IMM) fusion is facilitated by the optic atrophy 1 (Opa1) GT-
Pase [12]. Mitochondrial fusion plays an indispensable role in maintaining the homogeneity
of the mitochondrial matrix content across the whole mitochondrial network. Namely, dy-
namic equilibrium in mitochondrial DNA (mtDNA) content may help to equally distribute
the repertoire of different mtDNA variants throughout a heteroplasmic cell. The process of
mitochondrial fission is thought to be initiated by association with the endoplasmic reticu-
lum (ER), which pre-constricts the mitochondrial filament [13]. Upon stress stimulus, Drp1
is recruited to pre-constricted sites at the outer mitochondrial membrane (OMM) through
interaction with OMM receptors such as mitochondrial fission factor (Mff), mitochondrial
fission 1 (Fis1), or mitochondrial dynamic proteins 49 and 51 (MiD49 and MiD51) [14–16].
Following OMM binding and Drp1 oligomerization into spiral-shaped filaments wrapping
around the pre-constricted mitochondrial tubule, GTP hydrolysis induces conformational
changes that result in Drp1 ring closure and mitochondrial constriction [11,17]. Dnm2 is
then recruited to pre-constricted sites to complete the scission of both OMM and IMM [18].
Stress-induced mitochondrial fission is regulated by posttranslational modification of Drp1
such as phosphorylation, ubiquitination, SUMOylation, S-nitrosylation, O-GlcNAcylation,
and sulfenylation [10]. For example, phosphorylation of Drp1 at Ser616 and Ser637 has
stimulatory and inhibitory effects on its activity, respectively [18]. Lastly, but not less impor-
tantly, mitochondrial fragmentation occurs during mitosis to facilitate equal partitioning
of mitochondria between the two emerging daughter cells [19]. Mitotic division of mito-
chondria depends on the phosphorylation of Drp1 at Ser616 by cyclin B-cyclin-dependent
kinase 1 (Cdk1) kinase.
The ability of the mitochondrial network to dynamically change its interconnected
morphology to a fragmented one is key to the initiation of stress signaling pathways
that trigger mitophagy or apoptotic responses. However, the molecular mechanisms
underpinning these processes are largely unknown [10,20]. Several other proteins have
been found to regulate mitochondrial dynamics (Table 1).
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Table 1. Regulators of mitochondrial dynamics.
Name. Abbreviation References
Abelson tyrosine kinase c-Abl [21]
AMP-activated protein kinase AMPK [22,23]
calcineurin – [24–27]
Ca2+/calmodulin-dependent protein kinase CaMK [28,29]
c-Jun N-terminal kinase JNK [30]
cyclin C – [31,32]
cell division cycle 20 related 1 Cdh1 [33]
cyclin-dependent kinase 1 Cdk1 [19,24]
cyclin-dependent kinase 5 Cdk5 [34,35]
cyclophilin D – [36]
death-associated protein 3 DAP3 [37]
endophilin B1 – [38]
extracellular signal-regulated kinase Erk [39]
ganglioside-induced differentiation associated protein 1 GDAP1 [40]
hypoxia-inducible factor 1α HIF1α [41]
mitochondrial fission process 1 MTFP1 [42]
nuclear factor κB NF-κB [43]
nuclear factor (erythroid-derived 2)-like 2 Nrf2 [44]
overlapping activity with m-AAA protease 1 Oma1 [45]
mitofilin – [46]
p38 mitogen-activated protein kinase p38 MAPK [47]
PGAM5 – [48]
phospholipase D PLD [49,50]
protein disulfide isomerase A1 PDIA1 [51]
protein kinase A PKA [27,52]
protein kinase C, isoform δ PKCδ [24]
Rho-associated coiled-coil containing protein kinase 1 ROCK1 [53]
S6 kinase 1 S6K1 [54]
uncoupling protein 2 UCP2 [55,56]
2.2. The Crosstalk between Mitochondrial Shape Changes and Reactive Oxygen Species
Several key components of the mitochondrial dynamics machinery have been demon-
strated to depend on redox cues for activation in various disease settings [3]. For example,
previous work has shown that β-amyloid nitrosylates Drp1 at Cys644, which leads to
its activation, subsequent mitochondrial fragmentation, and neuronal injury suggesting
that NO-regulated mitochondrial fission may be a key contributor to Alzheimer’s disease
(AD) progression [57]. Drp1 was transnitrosylated via the intermediacy of Cdk5 in an-
other AD model [35]. Similarly, Watanabe et al. have observed enhanced mitochondrial
network fragmentation and mitochondrial function decline, which was associated with
increased insulin resistance, following H2O2 treatment in H9c2 cardiomyoblasts and these
effects occurred in a Drp1-dependent manner [58]. In addition, both overexpression of
long-chain acyl-CoA synthetase 1 and long-term palmitate treatment has been correlated
with increased levels of ROS and 4-hydroxy-2-nonenal, a marker of lipid peroxidation, in a
cardiomyocyte lipotoxicity model [59]. These mitochondrial shape changes were attributed
to reduced phosphorylation of Drp1 at Ser637 and altered proteolysis of Opa1. A thiol
reductase activity was found to be imperative for normal mitochondrial homeostasis in
endothelial cells since protein disulfide isomerase A1 (PDIA1) knockout mice displayed
aberrant phenotypes such as ER-facilitated and Drp1-dependent mitochondrial fission and
increased mitochondrial ROS generation resulting in cellular senescence [51]. The mecha-
nism was shown to involve a specific PDA1-Drp1 interaction as PDIA1 deficiency led to
Drp1 sulfenylation at Cys644. Nevertheless, it remains to be investigated further whether
H2O2 activates Drp1 directly or indirectly. Lastly, ionizing radiation in the form of γ-rays
or α particles induced mitochondrial fragmentation and accelerated mitochondrial super-
oxide formation in immortalized human fibroblasts or human small airway epithelial cells,
which was abrogated by Drp1 knockdown or inhibition, respectively [60].
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On the contrary, much less is known about the role of ROS in modulating pro-fusion
proteins. In this respect, one of the pivotal finding was the observation that oxidized
glutathione promotes mitofusin activation [61]. Cys684 of Mfn2 was later identified as
the key thiol switch responsible for regulating mitochondrial fusion induced by oxidized
glutathione. To outline, both mitochondrial fission and fusion proteins are subject either to
direct or indirect redox regulation pathways.
2.3. Damaged Mitochondrial Fragments Are Cleared by Mitophagy
Organelle-specific types of autophagy act on discrete cellular compartments to en-
zymatically digest and recycle their biochemical cargo inside autophagosomes that fuse
with lysosomes [62]. In contrast to general autophagy, which degrades cellular milieu
non-specifically, mitophagy selectively removes dysfunctional and fragmented organellar
segments. Upon mild stress, mitochondrial fragments compromised by deteriorating mito-
chondrial membrane potential are selectively pinched off the continuous mitochondrial
network reticulum by the action of the mitochondrial fission machinery [63]. Subsequently,
fragmented mitochondria are selectively recognized by the mitophagy machinery through
receptor binding between OMM and the growing membranous structure termed the
phagophore [64]. Following further extension, phagophore ultimately encapsulates the
damaged mitochondrion into a new structure called the mitophagosome [65]. This vesic-
ular organelle is composed of four membrane layers, two originate from the engulfed
mitochondrion and two from the phagophore itself. In the final step, lysosomal fusion with
mitophagosomes results in acidic hydrolysis of the mitochondrial content [65].
There are two basic modes by which the mitophagy assembly sequesters mitochondria
for degradation depending on the involvement of ubiquitin and whether the interaction
is direct or indirect [66]. In both cases, the interaction is mediated between microtubule-
associated protein 1 light chain 3 (LC3), found on the phagophore, and the mitochondrial
substrates [67]. In the ubiquitin-dependent pathway, LC3 indirectly binds to various
polyubiquitinated OMM proteins, such as voltage-dependent anion channel (VDAC),
Tom20, Mfn1, or Mfn2 [66,68]. These interactions are mediated by several factors including
dual-domain adapter proteins such as p62 (also known as sequestosome 1), nuclear dot
protein 52 (NDP52), Tax1 binding protein 1 (TAX1BP1), neighbor of BRCA1 gene 1 (NBR1),
and optineurin. In this configuration, the adapter protein contacts LC3 through its LC3-
interacting region (LIR) and binds to ubiquitin through its ubiquitin-binding domain
(UBD) [69]. In the ubiquitin-independent pathway, LC3 directly interacts with specific
OMM receptors such as Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)
and NIX (also known as BNIP3L) [64].
One of the most intriguing mechanisms by which mitochondria are marked for lyso-
somal degradation via ubiquitin-dependent mitophagy is the PTEN-induced putative
kinase 1 (PINK1)-Parkin system [66]. PINK1 is a serine/threonine kinase that is contin-
uously imported into the matrix of energized mitochondria by the translocases of the
outer (TOM) and inner (TIM) mitochondrial membrane [70]. During this process, PINK1
is proteolytically modified by the action of mitochondrial processing peptidase (MPP)
and presenilin-associated rhomboid-like protease (PARL). The truncated form of PINK1 is
consequently transported for proteasomal degradation into the cytosol. Dissipation of the
mitochondrial membrane potential, which can be experimentally induced by the addition
of a chemical uncoupler such as carbonyl cyanide m-chlorophenyl hydrazine (CCCP),
hinders mitochondrial import of PINK1 and results in its stabilization at the OMM as an
“eat-me” signal. Mitochondrial accumulation of PINK1 recruits the E3 ubiquitin ligase
Parkin to the mitochondrial surface, where it polyubiquitinates mitochondrial substrates
to tag the dysfunctional organelle for degradation in the lysosome.
2.4. The Complex Regulation of Intrinsic Apoptosis
There are two broad types of apoptotic cell responses, intrinsic and extrinsic. Whereas
extrinsic apoptosis relies on external stimuli for activation, which are sensed by plasma
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membrane death receptors, intrinsic apoptosis proceeds via a mitochondrial-dependent
stress-response pathway [71]. Intrinsic apoptosis can be triggered by both exogenous
or endogenous factors such as oxidative stress, DNA damage, mitochondrial membrane
potential collapse, and growth factor deprivation, or by developmental and physiological
cues. For example, oxidative stress is sensed by distinct redox-signaling pathways that
regulate activity of the mitochondrial dynamics machinery as a common platform for
governing cell survival or apoptosis [3]. In the first line of defense, cells adapt to mild or
transient stress by triggering mitophagy (Figure 1). The fragmented state of mitochondria
facilitates the progression of mitophagy as a quality control mechanism that selectively
removes dysfunctional mitochondria [10]. If the stress becomes severe or is persistent,
fragmented mitochondrial phenotype leads to the activation of intrinsic apoptosis [3].
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Figure 1. Mitochondrial network responds to oxidative stress by fragmentation. Mild oxidative stress
leads to the scission of individual dysfunctional mitochondrion (red) from functional organelles
(green), which are cleared by mitophagy. Persistent oxidative stress results in more profound
mitochondrial fragmentation, thus predisposing cells to death through apoptosis. A large variety of
chemotherapeutic agents elicit their cytotoxicity through elevating the oxidative status of the cell.
Apoptosis is tightly regulated by members of the B-cell lymphoma 2 (Bcl-2) family.
Depending on their characteristic content of highly conserved Bcl-2 homology (BH) do-
mains (BH1–4), these proteins can be divided into either pro-apoptotic or pro-survival [72].
Under basal conditions, the three domain-containing (BH1–3) effectors of apoptosis Bax
and Bak are mostly localized to the cytosol and OMM, respectively, in their compact non-
oligomeric forms [73]. Notably, Bax is believed to be in constant equilibrium between
the cytosol and the OMM [74]. Upon apoptotic stimuli, rates of translocation of Bax to
OMM exceed those of its retrotranslocation back into the cytosol resulting in its increased
mitochondrial retention [75]. This is accompanied by conformational changes in the ter-
tiary structure of Bax and its insertion into the outer leaflet of the OMM via its C-terminal
helix (α9) [76]. The progression of early stages of intrinsic apoptosis can be interrogated
by means of cell biology and molecular techniques directed at detecting mitochondrial
localization of Bcl-2 proteins and the membrane insertion or activation status of Bax or Bak.
Pro-survival proteins such as Bcl-2, B-cell lymphoma-extra large (Bcl-xL), and myeloid
cell leukemia 1 (Mcl-1), which contain all four BH domains (BH1–4), were implicated in
promoting cytosolic Bax sequestration to prevent cell death [77,78]. Direct activation or
derepression of negative regulation by pro-survival Bcl-2 proteins is mediated by the BH3-
only pro-apoptotic sub-class of proteins. This activity leads to additional conformational
changes in Bax and Bak structure that facilitate their oligomerization inducing outer mem-
brane permeabilization (MOMP) and release of pro-apoptotic factors such as cytochrome c
(cyt c), apoptosis-inducing factor (AIF), second mitochondrially-derived activator of cas-
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pase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO), Omi/high
temperature requirement protein A2 (Omi/HtrA2), adenylate kinase 2, deafness/dystonia
peptide (DDP)/TIMM8a and endonuclease G (endoG) [74,76,79,80]. The release of these
second messengers into the cytosol following MOMP is considered the point of no re-
turn during intrinsic apoptosis as OMM integrity is permanently lost. In addition to
spatiotemporal tracking of these second messengers, dissipation of mitochondrial mem-
brane potential may serve as an indirect measure of MOMP progression. Importantly,
novel nanoscopic techniques provided a proof-of-concept evidence for MOMP by visu-
alizing Bax-mediated pores following apoptotic stimulation at a resolution beyond the
diffraction limit [81].
Release of cyt c from IMM into the cytosol is essential for the allosteric activa-
tion of the downstream cascade of aspartate-specific cysteine endoproteases termed cas-
pases [82]. Initially, cyt c binds to apoptotic protease activating factor-1 (Apaf-1) in a
dATP/ATP-dependent manner, which induces a conformational change in this adapter pro-
tein. Upon nucleotide release, Apaf-1-cyt c heterodimers oligomerize into a multi-subunit
heptameric complex called the apoptosome. Mature apoptosome subsequently activates the
initiator caspase-9 through its caspase recruitment domain (CARD) [83]. Caspase-9, in turn,
binds and proteolytically activates executioner caspases 3 and 7. Furthermore, caspase acti-
vation can also be effected by a derepression mechanism, which involves relieved inhibition
of caspases from the inhibitor of apoptosis (IAP) protein family members, such as IAP1,
IAP2, or x-linked inhibitor of apoptosis (XIAP), by Smac/DIABLO or Omi/HtrA2 [84].
As part of the execution phase of regulated cell demise, these caspases dimerize and ac-
tivate a multitude of proteolytic and nucleolytic processes leading to the breakdown of
nuclear DNA (nDNA) and regulated decomposition of the cell [85]. The proteolytic signal
is further amplified and propagated by autocatalytic activation among the executioner cas-
pase enzymes themselves. Major targets of executioner caspases include poly(ADP-ribose)
polymerase (PARP), cytokeratin 18 (CK18), and inhibitor of caspase-activated DNase
(iCAD). Alternatively, apoptosis may proceed through a caspase-independent pathway,
in which AIF and endoG cooperate to directly induce nDNA fragmentation and chromatin
condensation.
2.5. Mitochondrial Fission Is the First Step in Intrinsic Apoptosis
Numerous reports have investigated the causal link between the mitochondrial mor-
phology and apoptotic activation [86–91]. The classic observation is that inhibition or
genetic inactivation of Drp1 delays cyt c release and cell death via apoptosis [92]. Moreover,
Bax has been shown to be recruited to Drp1-containing mitochondrial scission sites in
mammalian cell lines following apoptotic stimuli such as staurosporine treatment [93].
Although overexpression of a dominant negative mutant allele of Drp1 (dn-Drp1) had no
effect on Bax translocation, dn-Drp1-expressing cells were more resistant to staurosporine-
induced apoptosis. Using Drp1 knockdown, a follow-up work pinpointed the stimulatory
effect of Drp1 on apoptosis to occur downstream of mitochondrial Bax association but prior
to the onset of MOMP [94]. Collectively, this body of evidence suggests that mitochondrial
fragmentation promotes apoptosis at the level of Bax activation at the mitochondria and
that cell death can be delayed by inactivating mitochondrial fission. In another study,
researchers have found that Mfn1- or Mfn2 mitofusin-deficient mouse embryonic fibrob-
lasts (MEFs) display a fragmented mitochondrial phenotype and are more sensitive to
cisplatin treatment [95]. At the molecular level, increased sensitivity to cisplatin positively
correlated with Bax activation and its insertion into the OMM as well as with the release of
cyt c into cytosol. Furthermore, overexpression of Mfn1 or Mfn2 prevented mitochondrial
fragmentation, cyt c release, and apoptosis upon cisplatin or azide treatment in cervical
cancer HeLa cells when compared to empty vector control [95]. Analogous observations
were made following overexpression of dn-Drp1 and following azide treatment in rat renal
proximal tubule cells. Consistently, there was no difference observed in the translocation
of Bax to mitochondria between the empty vector control and either Mfn1, Mfn2, or dn-
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Drp1 overexpressing HeLa cells following azide treatment suggesting that mitochondrial
dynamics modulates intrinsic apoptosis downstream of mitochondrial Bax recruitment.
In line with these results, overexpression of Mfn2 prevented cell death in cerebellar granule
neurons exposed to various stress stimuli [96]. Although under very specific and unique
conditions, such as following Fis1 overexpression, mitochondrial fragmentation was shown
to drive the progression of intrinsic apoptosis, the consensus view is that mitochondrial
dynamics changes only sensitize cells to pro-apoptotic stimuli but do not necessarily com-
promise cell viability [97]. This notion is congruent with the reversible and flexible nature
of the mitochondrial network ultrastructure. Contrastingly, other reports have described
an inhibitory effect of mitochondrial fission on RCD suggesting a greater degree of molec-
ular and regulatory complexity in the underlying processes. Altogether, these findings
demonstrate that there is, indeed, an interplay between the mitochondrial fission and
apoptotic machineries and that mitochondrial fission-induced apoptotic induction may
be a conserved feature of both transformed and non-transformed cells. The mechanism
by which mitochondrial architecture remodeling predisposes cells to apoptosis is still an
ongoing scientific debate. Increased membrane curvature has been shown to both promote
and inhibit the recruitment of Bcl-2 family members to synthetic membrane vesicles there-
fore giving inconclusive answers. In an elegant study aimed at resolving this conundrum,
Montessuit et al. proposed that Bax oligomerization may predominantly proceed at the
constriction sites of mitochondrial membrane hemi-fission or hemi-fusion intermediates
and that cyt c release may therefore likely be concentrated to these microdomains [98].
How can apoptotic proteins be targeted for cancer therapy? The inherent resistance
of tumors to intrinsic apoptosis can be attributed to dysregulation of mechanisms at each
of the molecular steps of intrinsic apoptosis. In general, therapeutic approaches aim to
restore the delicate balance between pro-apoptotic and anti-apoptotic proteins. Given that
the increased expression levels of Bcl-2, Bcl-xL, and Mcl-1 are frequently observed in tumor
tissues, these proteins constitute important therapeutic targets for cancer therapy [84].
On the other hand, forcing cells into apoptosis by activating the BH3-only class of pro-
teins using small molecule compounds known as BH3 mimetics represents an alternative
path to cancer therapy [99]. The fact that antiapoptotic members of the Bcl-2 family are
frequently mutated in cancers adds an extra layer of complexity in targeting these proteins.
In summary, mitochondrial fission plays a vital role in the initiation of the reversible phase
of intrinsic apoptosis and manipulating the activity of this system can alter cell sensitivity
to anti-cancer drugs.
3. Reactive Oxygen Species and Cancer—A Dangerous Liaison
3.1. The Good and the Bad of Mitochondrial Reactive Oxygen Species
Owing to the fact that mitochondria harbor Complex IV as the terminal electron ac-
ceptor for oxygen utilization, these organelles are the largest intracellular source of oxygen
radicals [100]. ROS bear the harmful potential to oxidize lipids, nucleic acids, and proteins
making mitochondria the etiological origin of metabolic and degenerative diseases as well
as aging [101–103]. ROS are unavoidably generated by enzymes of the mitochondrial elec-
tron transport chain (ETC) during side reactions of electrons with molecular oxygen [104].
Other mitochondrial oxidoreductases reported to generate ROS are glycerol-3-phosphate
dehydrogenase, dihydroorotate dehydrogenase, electron-transfer flavoprotein-ubiquinone
oxidoreductase (ETF:QO), proline oxidase, and the dihydrolipoamide dehydrogenase sub-
complex of α-ketoacid dehydrogenases including pyruvate, α-ketoglutarate, α-ketoadipate,
and branched-chain α-ketoacid dehydrogenase [105]. Initially, superoxide anion radical
(O2•−) is produced by one-electron reduction of oxygen, which occurs predominantly at
Complex I and III redox sites [106]. Although superoxide has limited reactivity and does
not cross phospholipid membranes, it can be readily converted to H2O2, a nonradical
ROS, by superoxide dismutase (SOD) or non-enzymatically [107]. The family of SOD en-
zymes is comprised of three different isoforms depending on cellular localization. Whereas
copper/zinc isoforms of superoxide dismutase, SOD1 and SOD3, reside within mitochon-
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drial inter-membrane space (IMS) and extracellular space, respectively, the manganese
superoxide dismutase SOD2 is localized within the mitochondrial matrix [108].
One of the most active and damaging radical species is the hydroxyl radical (HO•) [109],
which can be produced from H2O2 in the presence of divalent metal ions, such as ferrous
iron, by the Fenton reaction [110]:
Fenton reaction: H2O2 + Fe2+ → HO• + OH− + Fe3+
The Fenton reaction can be extended into so-called Haber–Weiss reaction (see below,
top reaction), in which the iron ion acts as a catalyst, while cycling between its reduced
and oxidized state, for both the Fenton (bottom left) and superoxide oxidation (bottom
right) reactions [111]:
Haber−Weiss reaction : H2O2 + O2•−
Fe→ HO• + OH− + O2
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Other ROS types include singlet oxygen (1O2), nitric oxide (NO•), peroxynitrite
(ONOO−), alkoxyl radical (RO•), peroxyl radical (ROO•), and hypochlorous acid (HOCl).
Among these ROS, 1O2 has attracted eminent attention due to its central role as the active
species in photodynamic therapy (PDT) [112], whereas NO• and ONOO−, the only ROS
that overlap with the family of reactive nitrogen species (RNS) [113]. NO•, produced by
nitric oxide synthase in an oxygen-mediated NADPH-dependent oxidation of L-arginine
to L-citrulline, is freely diffusible albeit poorly reactive toward biomolecules. Nonetheless,
NO• can spontaneously and rapidly react with superoxide to yield a highly promiscuous
oxidant peroxynitrite:
NO• + O2•− → ONOO−
The mode by which radicals induce mutagenic DNA lesions entails direct damage
to nitrogen bases or DNA breaks. For example, hydroxyl radical-mediated oxidation of
guanine yields 8-oxo-7,8-dihydroguanine, which tends to pair with adenine to give rise to
a transversion mutation during replication. Given its close vicinity to ETC and the general
sparsity of mtDNA repair mechanisms, the mutation rate of mtDNA is estimated to be
around ten times higher than that of nDNA [114–116].
Oppositely to the harmful role originally proposed, the signaling potential of ROS has
been realized soon after their initial discovery [117]. The half-life of H2O2 is relatively long
and as a small, compact, and uncharged molecule, H2O2 is best suited, among all other
ROS types, to serve a signaling function [118]. Indeed, H2O2 can freely permeate biological
membranes, diffuse out of mitochondria, and equilibrate within various cellular compart-
ments to effect physiological responses. In addition, ROS are known to modify amino
acid side chains of proteins, particularly the sulfhydryl group of cysteine. In fact, cysteine
represents an important relay switch that reversibly alternates between the oxidized and
reduced state of redox-sensitive proteins, which are the integral part of redox-mediated
signaling cascades, and that of the tripeptide glutathione (γ-Glu-Cys-Gly), which forms
the basis for antioxidant redox buffering [3,119,120].
3.2. The Endogenous Antioxidant Defense Machinery
Intracellular and intramitochondrial levels of ROS are modulated by intricate antioxi-
dant defense systems that scavenge superoxide, H2O2, as well as other oxygen radicals to
protect cells from harmful effects of oxidative stress but also to fine-tune the redox microen-
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vironment for optimal redox signaling [121]. The most abundant intracellular antioxidant
molecule is glutathione, which cycles between its reduced (GSH) and oxidized (GSSG)
forms [120]. GSH can be synthetized de novo from L-glutamate, cysteine, and glycine
by glutamate-cysteine ligase and glutathione synthetase with γ-glutamylcysteine as an
intermediate. Among the ROS detoxifying enzymes, superoxide dismutase (SOD) and
catalase play the most prominent role as their concerted activity allows for the net reduction
of superoxide to H2O. SOD reaction involves the disproportionation of two superoxide
molecules to oxygen and hydrogen peroxide:
Superoxide dismutase: 2O2•− + 2H+ → O2 + H2O2
Owing to the role of mitochondrially-derived H2O2 as a key redox second messenger,
the cytosolic enzyme catalase plays an important function in redox signaling pathways by
decomposing H2O2 to oxygen and H2O:
Catalase: 2H2O2 → O2 + 2H2O
H2O2 can be also neutralized to H2O by the NADPH-dependent glutathione peroxi-
dase (Gpx) and glutathione reductase (GR) system:
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acid side chains, and is lfi i s ch as fibrinogen or human serum
albu in, although cyto-protection against HO• is orchestrated also at th l vel of iron
metabolism [1 2–124]. Moreover, dietary sup le ita in C and E, β-carotene,
as well as flavonoids are known quenchers of 1O2, potentially rendering PDT ap roaches
les efficient [125,126]. Finally, vitamin C and E as well as melatonin were reported to
scavenge RO• and RO • radicals while uric acid efficiently neutralized ONO − [127–129].
To conclude, oxidative stress can be attributed to the imbalance in redox homeostasis.
3.3. Apoptosis Is a Redox-Dependent Process
Since apoptotic resistance is associated with tumor initiation, cancer progression,
and metastasis, it is imperative to identify molecular processes that inactivate the safe-
guarding role of RCD [130]. Among the key factors contributing to apoptotic regulation
is cellular redox homeostasis [131]. ROS were reported to both positively and negatively
regulate apoptosis in a cell context-dependent manner [132]. For example, H2O2 activates
and recruits Bax to mitochondria via a mechanism involving cytosolic acidification in
colorectal carcinoma HCT116 cells [133]. This is consistent with the finding that Cys62 is
required for the H2O2-mediated activation of Bax in SW480 human colon adenocarcinoma
cells [134]. Similarly, Cys62 and Cys126 Bax residues were identified as intracellular redox
sensors for the initiation of Bax conformational changes during apoptosis induced by
selenite in in colorectal cancer cells. Using the general antioxidant N-acetyl-L-cysteine
(NAC), Zheng et al. [135] have demonstrated that both Bax translocation and activation
following As2O3 treatment in hematopoietic IM-9 cells occurred in a manner dependent on
ROS. However, the redox sensing mechanism for directing mitochondrial Bax translocation
remains unclear. Furthermore, the pro-oxidant state of Bax was necessary for cyt c release
and apoptosis progression induced by nerve growth factor (NGF) withdrawal in mouse
sympathetic neurons [136,137]. Taken together, these studies suggest that apoptosis may
be regulated through the oxidative status of Bax.
Given that enhanced ROS generation may stem from both metabolically active and dys-
functional mitochondria, it may be instrumental to tease out which of these two modalities
serves as the trigger for the intrinsic apoptotic form of RCD. Previous work has highlighted
the fact that OXPHOS facilitates stress-induced Bax- and Bak-dependent apoptosis in
human breast cancer MCF-7 and hepatoma HepG2 cell lines [138]. These observations are
consistent with the notion that ROS mediate the link between mitochondrial respiration and
apoptosis activation. Importantly, it has been suggested that it is the dependence of tumors
on glycolytic metabolism—a phenomenon termed as the Warburg’s effect—that renders
cancer cells resistant t pro-apoptotic insults. This would suggest that mitoc ondria are
highly functional before cells commit to apoptosis and that metabolic reprogramming
away fr m OXPHOS underlies cancer resistance. Mechanistically, the Warburg effect
p oduces reducing equivalents that help eutralize oxidative stress generated in tumor
cells d e to elevated metabolism. The crosstalk between OXPHOS and poptosis may
b conserved ac oss eukaryotes as it has been also described in yeast [139]. In contrast,
inhibiting ETC activity may stimulat apoptosis through mitoch ndrial ROS production.
Mecha istically, the site of ROS formation in h man breast cancer tumors might be Com-
plex III as withaferin A, a steroidal lactone from the w thanolide f mily isolated from the
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plant Withania somnifera, stimulated apoptosis through Complex III inhibition while the
effect was abolished upon SOD1 overexpression [140]. Conversely, ectopic expression of
the single-subunit yeast NADH dehydrogenase Ndi1 in Drosophila melanogaster led to
decreased mitochondrial ROS production, observed in isolated mitochondria respiring on
Complex I substrates, along with reduced apoptosis revealed by TUNEL staining in brain
sections of aged female flies [141]. To summarize, ROS-induced apoptosis can proceed
through inducing mitochondrial function or dysfunction in a context-dependent manner.
3.4. Reactive Oxygen Species as a Double-Edged Sword for Cancer
Increased levels of ROS as a result of metabolic rewiring are characteristic for many
tumor types as they are thought to promote proliferation and cancer cell survival during
tumorigenesis [8]. Examples of tumors that were confirmed to have high rates of ROS
formation include melanoma, neuroblastoma, liver hepatoma, ovarian, colon, pancre-
atic, and breast carcinoma [142–146]. Redox signaling plays a cardinal role during all
stages of carcinogenesis with the source of ROS being both mitochondrial and cytosolic
in origin [142,147]. Indeed, ROS has been reported to drive tumor initiation, transfor-
mation, proliferation, and dissemination [148]. Physiologically, elevated levels of ROS
promote mutagenesis, proto-oncogene activation, tumor suppressor inactivation, stim-
ulation of metabolic, autophagic, and signal transduction pathways, cell proliferation,
survival, adaptation to unfavorable microenvironment such as that found within the core
of solid tumor [149]. This tumor phenotype may be associated with resilience to therapeutic
approaches, increased risk of developing metastasis, and poor patient prognosis.
Conversely, excessive accumulation of oxidative stress in some cancer types can lead to
cell cycle arrest, apoptosis, or senescence [150]. Owing to its role in driving tumorigenesis,
intracellular ROS can be looked upon not only as a marker for oncogenic transformation
but also as a specificity guide for targeted anti-cancer therapy [151]. Given the differential
rates of ROS generation found within a tumor, identifying therapeutic windows for pro-
oxidant cancer therapy aimed to increase ROS levels above a putative threshold may be a
viable paradigm toward eliminating predominantly cancer but not normal cells (Figure 2).
Along these lines, endogenous ROS detoxifying systems, which are frequently upregulated
in tumors to escape cytoprotective mechanisms, are also widely recognized as potential
targets for anti-cancer therapy. In conclusion, ROS are a valid therapeutic target for cancer.
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Figure 2. The role of ROS in tumorigenesis. Cancer cells tend to upregulate ROS to support their
metabolic and proliferative potential. Increased oxidative stress may, in turn, contribute to the
mutational burden of these tumors. Pro-oxidant chemotherapeutic or radiotherapeutic approaches
may be deployed to elicit cell cycle inhibitory, apoptotic, or senescent outcomes after overcoming a
specific threshold, which is distinctive between cancer and the healthy tissues (dashed line).
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4. Surpassing the Redox Threshold for Apoptosis in Tumors by Inducing
Mitochondrial Fission
4.1. Cyclin C Acts as a Bridge between Stress-Induced Mitochondrial Fission and Apoptosis
Activating mitochondrial fission, instead of inhibiting it, to combat cancer is a rel-
atively novel concept [87,152]. Many of the previous chemotherapeutic attempts were
focused on targeting pro-fission factors such as using the Drp1 inhibitor mdivi-1 [153].
These approaches were predominantly motivated by upregulation of Drp1 and the conse-
quent fragmented mitochondrial phenotype morphology commonly observed in cancers.
As an alternative, one can imagine a strategy whereby a pulse of mild oxidative stress
would activate the mitochondrial fission-apoptosis redox axis (Figure 3).
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Figure 3. Inducing mitochondrial fission process as a co-adjuvant approach to current chemothera-
peutic strategies. Pharmacological interventions aimed at inducing mild oxidative stress can lead
to Drp1 activation (red), increased mitochondrial fragmentation and ROS production. This, in turn,
activates pro-apoptotic effector protein Bax (green), which oligomerizes to induce MOMP-dependent
cytochrome c (cyt c) release (pink) thereby rendering tumor cells (black) more sensitive to ROS-
inducing anti-cancer drug such as cisplatin.
Indeed, such a model has been verified experimentally. Pretreatment of the model
cervical cancer HeLa cells with a stapled peptide mimetic (S-HAD) that disrupts the
interaction between the highly conserved tumor suppressor cyclin C, a transcriptional
regulator canonically found in the nucleus, and the Mediator, a transcriptional coactivator
complex of RNA polymerase II, led to effective sensitization of these cells to cisplatin
treatment [87]. The rationale behind this strategy was based on previous experiments
in yeast wherein cyclin C is released from Med13p binding in the nucleus following
various forms of cellular stress. Cytoplasmic cyclin C induced extensive fragmentation
of the mitochondrial network [32]. Moreover, depletion of Med13p was sufficient to
induce mitochondrial fission and sensitized yeast cells to H2O2 treatment [154]. In fact,
Med13p destruction was later shown to be a critical part of the oxidative stress sensing
mechanism that regulates nuclear release of cyclin C, which relies upon the mitogen-
activated protein kinase (MAPK) signaling pathway for activation [155]. Summarily,
nuclear cyclin C release represents a bona fide redox signaling pathway impinging on
mitochondrial dynamics proteins.
What is the mechanism by which cytosolic cyclin C effects mitochondrial dynamics
and cell viability? The role appears to be direct and independent of the transcription
regulatory function of cyclin C. In mammalian and yeast cell cultures, cyclin C was shown
to interact with Drp1 and Dnm1, the yeast ortholog of Drp1, respectively, to promote
mitochondrial fission and stress-induced apoptosis [31,32]. The association between cyclin
C and Drp1 was also analyzed in vitro [17]. The results indicated that cyclin C binds the
GTPase domain of Drp1 through its second cyclin box domain. Nevertheless, the most
fundamental observation that pointed to the pro-apoptotic function of cyclin C as a solid
tumor suppressor was that MEF cells lacking cyclin C were resistant to cisplatin-induced
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apoptosis [31]. Unraveling the mechanism of the stress response pathway mediated by
cyclin C further revealed that S-HAD or H2O2 treatment led not only to mitochondrial
fragmentation but also to enhanced mitochondrial Bax recruitment and activation and
this occurred in both cyclin C- and mitochondrial ROS-dependent manner [87]. Curi-
ously, although S-HAD-induced mitochondrial fragmentation positively correlated with
increased production of mitochondrial superoxide, S-HAD treatment had no significant
effect on cell viability. Hence, it is the contribution from three oxidative stresses, one from
the transformed tumor itself, second from cisplatin, and the third from S-HAD-induced
mitochondrial fission, that act in synergy to surpass the threshold for apoptotic cancer
cell killing. Accordingly, one can conjecture that it is not the fragmented phenotype per
se that leads to the activation of apoptotic processes but instead the sudden change in
mitochondrial morphology, which is required to trigger the maximum production of ROS.
Further evidence for a role of cyclin C as a tumor suppressor was demonstrated
in organs isolated from thyroid-specific [156] and pancreas-specific (R.S. and Kerry S.
Campbell, Fox Chase Cancer Center, Philadelphia, PA unpublished observations) CCNC
knockout mouse. Despite the mitochondrial fission-promoting response of cyclin C to H2O2
or S-HAD could be recapitulated in murine poorly differentiated thyroid cancer (PDTC) cell
line, this effect may be uncoupled from Bax activation as there was no difference observed
between the numbers of apoptotic cells in the control and CCNC siRNA cells following
cisplatin treatment. Overall, these data suggest that pharmacological activation of the
cyclin C pathway may be a promising chemotherapeutic strategy to treat solid tumors.
However, more investigations are needed to confirm the utility of such a combination
chemotherapy approach, particularly with respect to taking advantage of a xenograft
mouse model. A careful examination of the mitochondrial fission process will also be
needed to elucidate the spatiotemporal kinetics of mitochondrial function before the onset
of MOMP. Namely, the principal question to be addressed in the future therefore is whether
mitochondrial fission-stimulated ROS production is a result of increased or decreased
mitochondrial function? Also, pinpointing the source of the mitochondrial ROS would help
to contribute to a more thorough understanding of the underlying signaling mechanism.
4.2. Does a Self-Perpetuating Cycle of Mitochondrial Fission and Reactive Oxygen Species
Production Underpin the Mechanism of Apoptotic Sensitization?
Notwithstanding the exact mechanism involved, one may speculate whether there
is a self-potentiating continuum between redox sensing, such as mediated by cyclin C,
and mitochondrial fission-induced ROS production, which may contribute to more effective
killing of cancer cells upon the administration of chemotherapy co-adjuvants stimulating
mitochondrial fission, such as S-HAD (Figure 4). This scenario assumes that, in addition to
the nuclear-to-mitochondrial signaling effected by cyclin C, there is a retrograde communi-
cation between mitochondria and the nucleus mediated by an unknown second messenger,
which could potentially be H2O2. Regarding the molecular mechanism involved, we can
only speculate whether the retrograde signaling role is solely elicited by H2O2 or whether
additional ROS-dependent processes such as mitophagy or lipid peroxidation are being
concurrently activated. Although the proposed signaling mechanism inarguably deserves
future scrutiny, the resultant net effect of S-HAD treatment is the sensitization of tumors to
apoptosis-inducing chemotherapy [87].
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